BridgeBio Oncology Therapeutics, Inc. 8K

BridgeBio Oncology Therapeutics issued a corporate update reprioritizing its RAS‑pathway oncology pipeline toward BBO‑8520 combo in G12C inhibitor–experienced NSCLC and BBO‑11818/BBO‑10203 combinations in KRAS‑mutant cancers, while indicating cash runway into 2028.

BridgeBio Oncology Therapeutics, Inc. used this Form 8‑K exhibit to provide a September 2026 corporate update describing strategic reprioritization of its RAS‑pathway oncology pipeline, including deprioritizing BBO‑8520 in first-line non-small cell lung cancer and BBO‑10203 in breast cancer due to evolving standards of care and competitive dynamics, while concentrating resources on the BBO‑8520 plus pembrolizumab combination in second‑line and later KRAS G12C inhibitor–experienced NSCLC patients and on advancing BBO‑11818 and BBO‑10203, alone and with standard-of-care agents, in KRAS‑mutant colorectal and pancreatic cancers; the update also highlights early Phase 1 efficacy and safety data across these programs and states that the company’s cash position of approximately $344 million as of Q2 2026 is expected to fund operations into 2028, including completion of Phase 1 development for its three clinical programs.

Filing Facts

CIK

1869105

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-385225

Alert Tier

6